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whose core competencies involved the research and development
(R&D) of pharmaceutical, medical, or biotechnological innova-
tion. METHODS: Regression methods were utilized for a sample
of 50 highly-innovative parent companies from 1985 to 1998.
Dependent variables included stock market capitalization and
returns. Independent variables included, but were not limited to,
risk, patent activity, new molecular entity (NME) approvals, and
R&D expenditures. RESULTS: Semi-elasticities of market capi-
talization with respect to ﬁrm-level determinants of innovative
activity generally differed as a function of ﬁrm size. Measures of
innovative output, including patents and NMEs, were signiﬁcant
only for the larger ﬁrm classiﬁcations, while R&D expenditures
were signiﬁcant for all group classiﬁcations. Smaller companies
received higher relative valuations per million dollars spent on
R&D than their larger rivals, and large ﬁrms received higher val-
uations based upon a one percent increase in R&D budgets. The
analysis of stock market returns indicated that larger companies
received returns, which were more consistently positive and less
volatile, even though mean returns between groups were not sta-
tistically different. Accounting for the skewed nature of these
data, the median returns differed substantially based upon ﬁrm
size. The multivariate analysis of these returns did not reveal a
trend that was consistent with either R&D inputs or outputs.
CONCLUSIONS: Considerable differences in the valuation
makeup of companies were observed between ﬁrm size. Dimin-
ishing semi-elasticities existed with respect to increasing ﬁrm size
for many of the variables in the econometric analysis. Numer-
ous phenomena appeared to impact stock market returns, 
indicating challenges in the appropriate valuation of companies
concerning future R&D beneﬁts, or that positive returns were
not guaranteed even though overall R&D expenditures or inno-
vative output increased.
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OBJECTIVE: Given the increased interest in conducting phar-
macoeconomics and outcomes studies post-launch, the objective
of this study was to explore the desirability and feasibility of dif-
ferent types of studies. METHODS: The published literature on
post-launch studies was reviewed and the recommendations for
further research made by the National Institute for Clinical
Excellence (NICE) in the UK were analysed. In addition, global
heads of pharmacoeconomics and outcomes research (PE/OR) in
major pharmaceutical companies were surveyed to ascertain
their experience in conducting studies post-launch and the prob-
lems encountered. RESULTS: In the ﬁrst 46 technology appraisal
of drugs conducted by NICE, recommendations for further
research included head-to-head studies of the new drug with rel-
evant alternatives (39% of appraisals); better information on
impacts on quality of life (43%); longer term evidence on com-
pliance, adverse events or maintenance of clinical effect (41%);
study of the drug in relevant patient sub-groups (33%); and
understanding the most cost-effective use of the drug in routine
practice (43%). The survey of heads of PE/OR departments
revealed a wide variety of experience with conducting post-
launch studies. The problems identiﬁed included the need for
large sample sizes, difﬁculties in ﬁnancing studies and the
unfavourable risk-beneﬁt of some studies from a commercial per-
spective. CONCLUSIONS: Whilst it is desirable to conduct
pharmacoeconomics and outcomes research post-launch, those
bodies recommending such studies should pay more attention to
the practical and methodological challenges raised by certain
study designs.
PHP41
PARALLEL TRADE OF PHARMACEUTICALS AS A 
COST-CONTAINMENT MEASURE-ANALYSIS OF THE 
ISRAELI EXPERIENCE
Eldar-Lissai A1, Shvarts S2, Goldberg A2, Shani S2
1University of Rochester, Rochester, NY, USA; 2Ben-Gurion University
of the Negev, Israel
The Israeli Law enabling parallel import of pharmaceuticals was
implemented in January 2001. Prior to its legislation there was
only one exclusive importer for each pharmaceutical product,
imported directly from the manufacturer. Parallel import enables
the importation of a given pharmaceutical to Israel by a number
of importers—not necessarily directly from the manufacturer,
thus amplifying economic competition, which should result in
lower acquisition price. OBJECTIVES: Our study examines the
impact of the law three years after its implementation, regard-
ing the national expenditure on pharmaceuticals. METHODS:
Since ﬁnancial data is not available to the public, the study was
based on qualitative data. A survey of senior management of the
Israeli health care system was conducted. A pool of 50 execu-
tives was constructed, representing all relevant stakeholders.
Each participant was interviewed face-to-face, using a uniform
questionnaire. RESULTS: The response rate was 68%, all sectors
had at least one representative. The preliminary analysis of the
answers shows that although during 3 years, only 22 drugs were
parallel imported, most of the responders answered that both 
the national expenditure and prices of pharmaceuticals were
reduced. No damage was done to the publics’ health, and there
was no change in the number of newly approved pharmaceuti-
cals. CONCLUSIONS: As a result of the Parallel Import legis-
lation, combined with several other cost-containment reforms, a
reduction in the prices of pharmaceuticals is noticed. The fact
that only 22 pharmaceuticals, and none during 2003, were actu-
ally imported by parallel trade shows that the main reduction is
attributed to lower prices established by the manufacturers them-
selves, trying to avoid competition from parallel imports. Thus,
the importance of the law lies not necessarily by carrying it out,
but simply by the fact that it allows the major buyers to use it
as a tool in the negotiation with manufacturers.
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OBJECTIVE: Although drug manufacturers have gained com-
petence in pharmacoeconomic analysis, they have been slow to
bring these tools and techniques to bear on important “go/no-
go” decisions for compounds in development. This may be due
to difﬁculties in modeling the cost-effectiveness of products that
have yet to undergo clinical trials, wherein critical data on
important model parameters would be collected. Yet, in the
current cost-conscious environment, it is risky to invest in the
development of a product without ﬁrst exploring its potential
pharmacoeconomic proﬁle. METHOD: We developed an ana-
lytic apparatus for use in conjunction with traditional cost-
effectiveness models to illustrate how good a developmental
compound would need to be in terms of key clinical parameters
(e.g., adverse event rate, failure rate) for it to be cost-effective
versus competing products. Borrowing constructs from micro-
economic theory, we demonstrate how two-way threshold analy-
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ses on a new product’s adverse event rate and failure rate can 
be used to trace “iso-cost” and “iso-QALY” curves depicting
combinations of these parameters yielding equivalent costs and
QALYs, respectively, compared to an existing standard of care.
RESULTS: Graphical analyses of the iso-cost and iso-QALY
curves highlight four distinct regions of parameter combinations
in which a new product would be dominant, incrementally cost-
effective (at a given threshold), incrementally cost-ineffective, or
dominated. Prior probability distributions on these parameters
can be used to predict the likelihood of being in each of these
regions, and value-of-information analysis can be used to assess
formally the expected net beneﬁt of proceeding with clinical
development, reﬂecting the present value of its future revenue
stream less the total costs of bringing it to market. Modeling per-
formed in psychiatry will be used to illustrate the concepts.
CONCLUSIONS: Methods for “go/no-go” modeling of com-
pounds in the development pipeline provide a means of incor-
porating pharmacoeconomic criteria into drug development
decision-making.
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OBJECTIVES: To assess the impact various price control 
mechanisms (PCM), including re-importation, would have on
the incentives for R&D investment in the pharmaceutical and
biotechnology industries. METHODS: A simulation model,
based on the most recently compiled estimates of the costs and
returns to R&D investment in the pharmaceutical industry is
used to estimate the distribution of expected NPV at the time
products enter clinical testing. The model estimates the impact
of various PCMs on this distribution, and on the resulting R&D
investment ($ and % age) that meet the necessary NPV > 0
threshold. RESULTS: Under the naïve model of no project spe-
ciﬁc information, the model shows that there would be little
impact of implementing price controls if ﬁrms could be assured
that these controls would not reduce prices by more than 25%.
However, preliminary results show that if ﬁrms believed that
price controls would exceed this threshold, they would suspend
all investment in new R&D projects. Under more realistic
assumptions, the impact of even mild price controls leads to an
immediate cut-backs in R&D projects as marginal projects are
eliminated. An anticipated 25% reduction in future US prices
would decrease R&D project by approximately 50% and R&D
investment by approximately 33%. CONCLUSIONS: Our sim-
ulation model shows that pharmaceutical industry investment in
R&D is very sensitive to price controls in the US.
